Personalized dendritic cell-based tumor immunotherapy

Nona Janikashvili, Nicolas Laemonier, Emmanuel Katsanis

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their limitations and the future challenges for effective immunotherapy against cancer.

Original languageEnglish (US)
Pages (from-to)57-68
Number of pages12
JournalImmunotherapy
Volume2
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Immunotherapy
Dendritic Cells
Vaccines
Neoplasms
Cancer Vaccines
Autoantigens
Immune System
Animal Models
Therapeutics

Keywords

  • Anticancer immune response
  • Chaperone protein
  • Dendritic cell idiotype
  • Personalized tumor vaccine
  • Tumor lysate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Personalized dendritic cell-based tumor immunotherapy. / Janikashvili, Nona; Laemonier, Nicolas; Katsanis, Emmanuel.

In: Immunotherapy, Vol. 2, No. 1, 01.2010, p. 57-68.

Research output: Contribution to journalArticle

Janikashvili, Nona ; Laemonier, Nicolas ; Katsanis, Emmanuel. / Personalized dendritic cell-based tumor immunotherapy. In: Immunotherapy. 2010 ; Vol. 2, No. 1. pp. 57-68.
@article{b03cb16ff44241e1b45ad010c35ce847,
title = "Personalized dendritic cell-based tumor immunotherapy",
abstract = "Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their limitations and the future challenges for effective immunotherapy against cancer.",
keywords = "Anticancer immune response, Chaperone protein, Dendritic cell idiotype, Personalized tumor vaccine, Tumor lysate",
author = "Nona Janikashvili and Nicolas Laemonier and Emmanuel Katsanis",
year = "2010",
month = "1",
doi = "10.2217/imt.09.78",
language = "English (US)",
volume = "2",
pages = "57--68",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Personalized dendritic cell-based tumor immunotherapy

AU - Janikashvili, Nona

AU - Laemonier, Nicolas

AU - Katsanis, Emmanuel

PY - 2010/1

Y1 - 2010/1

N2 - Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their limitations and the future challenges for effective immunotherapy against cancer.

AB - Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their limitations and the future challenges for effective immunotherapy against cancer.

KW - Anticancer immune response

KW - Chaperone protein

KW - Dendritic cell idiotype

KW - Personalized tumor vaccine

KW - Tumor lysate

UR - http://www.scopus.com/inward/record.url?scp=77953391020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953391020&partnerID=8YFLogxK

U2 - 10.2217/imt.09.78

DO - 10.2217/imt.09.78

M3 - Article

VL - 2

SP - 57

EP - 68

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 1

ER -